Skip to main content

Time in Range News

Time in Range (TIR) is the percentage of time that a person spends with their blood glucose levels in the target range, usually between 70 and 180 mg/dl.

Read about a new cauliflower pizza crust, alongside updates on Senseonics Eversense CGM, Medtronic’s new CGM points program, the Beyond A1C movement, Tandem’s Basal-IQ,...
Updates to the Clarity app allow G5 and G6 CGM users to set a daily time-in-range goal and be notified when it is reached, awesome Bright Spots pattern recognition in...
The most promising therapies in the pipeline, accuracy data on the FreeStyle Libre 2, and more
The latest updates on time-in-range goals for people with all types of diabetes, and insights linking FreeStyle Libre scanning frequency to outcomes.
The benefits of measuring time in range, plus new care guidelines for adults with type 2 diabetes
Control-IQ hybrid closed loop coming in summer 2019; paired app coming soon to the US; plans for the t:sport “patch” pump; and t:slim X2 pump launched outside the US
The SWITCH PRO trial will examine whether Tresiba improves blood sugar management more than Lantus, as measured by FreeStyle Libre Pro; now recruiting at 67 locations...
The diaTribe team was on the ground at the 2019 ADA 79th Scientific Sessions to share several of the greatest highlights from the conference!
Tubeless Omnipod will communicate directly with Tidepool Loop app. Insulet’s own Horizon hybrid closed loop expected to launch in second-half of 2020
As 2019 comes to an end, we reflect on a year of hope and growth, with immense gratitude for our community. In 2020 we will continue to focus on helping people with...
New updates include time-in-range goals, heart health benefits of GLP-1 agonist Trulicity, and recommendation of GLP-1 agonist Victoza for children and teens with type 2...
Control-IQ Hybrid Closed Loop on track to launch in the US by the end of 2019 for those ages 14 and older; first system with automatic correction boluses and no...
New updates include the recommendation of GLP-1 agonists and SGLT-2 inhibitors for heart and kidney protection, earlier combination therapy in type 2 diabetes, GLP-1...
This currently recruiting study will support FDA submission of Tandem’s Control-IQ hybrid closed loop for children six years of age or older
The diaTribe team was in Barcelona for the 55 th Annual Meeting of the European Association for the Study of Diabetes. Check out our biggest highlights from the...
The tool for people with diabetes to use with their healthcare professionals will launch in early 2020, extending CGM further! Features include fully disposable...
What is it like having a sibling with diabetes, and what can someone do to support their sibling with diabetes? 20-year-old Alexandra Varon shares insight on having a...
What I've Learned From 70,000 Hours Wearing CGM - A Video Presentation at Thriveabetes 2019
Diabetes advocates, Renza and Grumpy, share the importance of #LanguageMatters and the consequences of “grading” diabetes management
This study, now recruiting 350 participants, will examine the safety of the MiniMed 780G Advanced Hybrid Closed Loop System in people with type 1 diabetes (7+ Years)

Pages